INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer worldwide. The lymph node (LN) is the most common site of metastasis, and the LN status is the most powerful prognostic factor. The Guidelines for Tumor Node Metastasis (TNM) staging are provided by the American Joint Committee on Cancer (AJCC) and the Union of International Cancer Control (UICC). LN (N category) staging includes information on the number of positive lymph nodes.

The advantage of one-step nucleic acid amplification for the diagnosis of lymph node metastasis in colorectal cancer patients

Yukiharu Hiyoshi | Takashi Akiyoshi | Yosuke Fukunaga

Gastroenterological Center, Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Correspondence
Yukiharu Hiyoshi, Gastroenterological Center, Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
Email: yukiharu.hiyoshi@jfcr.or.jp

Abstract
Generally, the postoperative examination of lymph nodes (LNs) is based on a microscopic examination of one hematoxylin and eosin (HE)-stained slide; however, an examination of only one part of the LN might lead to incorrect staging of the tumor due to tissue allocation bias. Although multilevel sectioning and the use of immunohistochemistry (IHC) have improved the detection of micrometastases in LNs, this approach is laborious, time-consuming, and costly. A novel molecular technique for the detection of LN metastases of tumors, called one-step nucleic acid amplification (OSNA), is a rapid and semi-quantitative examination quantifying the number of cytokeratin 19 (CK-19) mRNA copies derived from a tumor. OSNA is already in clinical use for the diagnosis of LN metastasis in breast cancer patients; however, the use of OSNA is under investigation with promising results for colorectal cancer (CRC). The present review assessed recent studies on OSNA vs a histopathological examination and its implications for CRC staging and treatment. A total of 16 studies of OSNA in CRC yielded by a PubMed search were reviewed. Among them, seven studies evaluating the diagnostic performance revealed that OSNA had a high specificity (96.8%), high concordance rate (96.0%), and negative predictive value (98.6%) in a pooled assessment. In addition, four studies examining the utility of OSNA in sentinel LNs (SLNs) and two studies focusing on upstaging in pathologically node-negative CRC patients were also reviewed. Multicenter prospective studies with a large cohort of CRC patients are warranted to reveal the benefits of OSNA in the future.

KEYWORDS
CK-19, colorectal cancer, lymph node metastasis, micrometastasis, OSNA, sentinel lymph node
on whether or not the cancer has spread to regional LNs and how many LNs are involved. Isolated tumor cells (ITCs) in LNs are defined as single cancer cells or small clusters of tumor cells measuring ≤0.2 mm and classified as N0 (i-). Micrometastases are defined as tumor clusters measuring >0.2 mm but ≤2.0 mm in their greatest dimension and classified as N1 (mic). Although the prognostic value of ITCs is unclear, a recent systematic review and meta-analysis showed micrometastasis to be a significantly poor prognostic factor.3 Per the AJCC 8th edition, the micrometastasis may be designated as N1 (mic), but that may be better considered standard positive LNs. Because of the strong prognostic relevance of LN metastases in CRC, the presence of occult tumor cells, defined as micrometastases or ITCs within regional LNs that are not detected on a conventional histopathologic examination using hematoxylin and eosin (HE) staining has been suspected to be a marker of systemic tumor spread in these patients.4 Therefore, the detection of occult disease may help identify patients with node-negative CRC who are at a high risk of tumor recurrence and who might benefit from adjuvant therapy.

Combining routine HE staining with tumor-specific immunohistochemistry (IHC) using step sectioning specimens or molecular detection techniques, such as reverse transcriptase polymerase chain reaction (RT-PCR), provides a higher sensitivity than routine histology alone.5,6 However, these methods are burdensome and time-consuming, so a quick, highly sensitive, and specific diagnostic technique that enables a prompt intraoperative examination is necessary.

A new molecular technique called one-step nucleic acid amplification (OSNA), which is a rapid and semi-quantitative intraoperative procedure for quantifying the number of cytokeratin 19 (CK-19) mRNA copies in LNs, has been employed to assess the LN progression of tumors. OSNA was first reported in breast cancer patients and has been shown to be effective for detecting nodal metastases.7 OSNA can assess the occurrence of metastasis in the whole LN regardless of tissue allocation biases and estimate the total volume of tumor cells semi-quantitatively. This is one important advantage of OSNA over a pathological assessment.

Although the validity of OSNA assay for detecting LN metastasis has also been widely reported in patients with other types of malignancies, such as CRC, lung cancer, gastric cancer, head and neck squamous cell carcinoma (HNSCC), and thyroid cancer, its clinical benefit has not been established.8,9 In addition, several studies have recently evaluated OSNA for LN metastasis in CRC, focusing on pathological stage II disease, sentinel LN (SLN) metastasis, and lateral pelvic LN (LPLN) metastasis.

We herein review studies relevant to OSNA in CRC and discuss perspectives on the future applications of this assay.

2 | LITERATURE SEARCH

A search for medical reports relevant to OSNA in colorectal cancer published before the end of June 2020 was made through PubMed using the keywords of “OSNA” and “colorectal cancer” or “colon cancer” or “rectal cancer.” Reports written in languages other than English were excluded. Review articles were also excluded. The 16 studies obtained by the PubMed search are shown in Table 1.

3 | THE IDENTIFICATION OF AN OPTIMAL mRNA MARKER FOR THE OSNA ASSAY IN CRC

At present, the validity of the OSNA assay targeting CK19 mRNA for detecting LN metastasis has been widely reported in patients with various types of tumors, including CRC. Yamamoto et al reported the background for the identification of CK19 mRNA as an optimal marker for the OSNA assay in CRC.10 Ninety-eight candidate mRNAs selected from the genome-wide expressed sequence tag database were evaluated by quantitative RT-PCR using a mixture of metastasis-positive LNs and another mixture of metastasis-negative LNs in CRC patients. Thereafter, the three identified candidates (CK19, CEA, and CK20) were examined by an OSNA assay, and CK19 mRNA was found to have the best diagnostic performance. The cut-off value for discriminating positive from negative LNs was set at 75-500 copies/µL, with 96.4% sensitivity and 100% specificity.

4 | DIAGNOSTIC PERFORMANCE OF THE OSNA ASSAY IN CRC

Among the 16 studies listed in Table 1, the seven comparing the diagnostic performance between the OSNA and a pathological examination for the detection of LN metastasis in CRC are shown in Table 2. The calculated values of sensitivity, specificity, concordance, positive predictive value (PPV), and negative predictive value (NPV) in a pooled analysis were 90.4%, 96.8%, 96.0%, 79.8%, and 98.6%, respectively. These values are similar to those of breast cancer previously reviewed by Tamaki et al.6

It should be noted that the methodology of the histopathological evaluation for detection of the LN metastasis differed among studies. For example, a standard pathological examination using HE staining with a single 4-µm-thick tissue section was used in some studies,15,19,21 while a more precise pathological evaluation for the detection of LN metastasis, such as macrometastasis, micrometastasis, and isolated tumor cells (ITCs), was attempted, and the diagnostic accuracy was compared between an intensive pathological evaluation and the OSNA assay in others.10-12,22 Studies conducted by Yamamoto et al11 and Yeung et al21 pathologically evaluated LN metastasis using HE staining with multi-sliced tissue sections, and Croner et al26 examined LNs using not only HE staining but also CK19 IHC. Guller et al compared the performance of the OSNA with both standard HE staining (single section) and intensive histopathology (HE staining and CK19 IHC with 0.2-mm skip-sliced sections) in the detection of colon cancer LN metastasis, and the OSNA had a similar performance for detecting LN metastasis to intensive histopathologic investigations and appeared to be superior to standard histology with HE staining.12 The fact that the pooled PPV of OSNA
(79.8%) was lower than other values as shown in Table 2, shows that the false-positive rate of OSNA is high. This may be because the OSNA assay can detect some LN metastases of CRC that cannot be detected by histopathological examinations due to tissue allocation biases or insufficient performance for the detection of micrometastasis.

The studies listed in Table 2 evaluated the diagnostic accuracy, comparing the OSNA and histopathological examination in resected LNs one by one. However, given the high prevalence of CRC and the high number of LNs to be analyzed, systematic molecular LN analyses and additional diagnostic methods beyond routine HE are unlikely to be incorporated into the pathological diagnosis, largely because of the high cost of molecular techniques and the supplementary workload. To resolve this issue, Rakislova et al\textsuperscript{16} conducted a study comparing two methods of the OSNA for detection of LN metastasis in CRC: an individual analysis of each LN and a new approach involving pooling several LNs, known as the “pooling method.” The diagnostic performance of the OSNA with the pooling method was comparable to that of the individual analysis, and the authors concluded that the pooling strategy was a rapid method that can be routinely performed and would aid in the therapeutic management of CRC patients.

5 | THE OSNA ASSAY FOR THE DETECTION OF CRC METASTASIS IN SLNs

In CRC, the SLN concept was introduced in 1999 by Joosten et al\textsuperscript{27} in order to reduce the false negative result rates and to understand the importance of the LN involvement for further therapy and the survival rate of these patients. SLNs are considered to be the LNs located closest to the tumor in the lymphatic drainage pathways, bearing the highest risk of tumor involvement.\textsuperscript{27} Using lymphatic mapping, two to four such LNs may be identified.

The principle of an SLN biopsy is well established in melanoma and breast cancer, where the aim is to avoid unnecessary and potentially morbid lymphadenectomy. Unlike these two malignancies, where lymphadenectomy is a separate procedure, lymphadenectomy in elective CRC surgery is typically performed as part of a single surgical procedure. Therefore, an SLN biopsy to omit unnecessary lymphadenectomy does not seem clinically useful in CRC surgery. However, if an SLN biopsy can readily and reliably determine the LN status, permitting more conservative surgery, then reduced tissue dissection, shortened operative time, and a better bowel function are all desirable outcomes, especially in early-stage CRC patients.
The main advantage of SLN mapping in CRC appears to be the identification of nodes that carry an increased risk of metastasis, as these LNs can then be subjected to detailed scrutiny, including more sections and IHC, thereby optimizing the staging accuracy. While whether or not LN mapping can improve the outcomes for CRC patients is unclear because the influence of the detected micrometastasis on the survival and therapeutic decision is controversial, different studies have shown that ex vivo SLN mapping is an easy and feasible technique for CRC patients. This technique was characterized by a high accuracy of 90%-100% and NPV of 80%-100%, and upstaging has been observed in 19%-57% of cases.

With the advent of the OSNA technique, which enables the whole-tissue assessment of LN metastasis rapidly, the merits of the SLN concept may be reconsidered.

Previous studies analyzing CRC metastases in SLNs with the OSNA are listed in Table 3. The injected dyes for the detection of SLNs were blue dye or indocyanine green. An intraoperative OSNA assay was performed in two studies, and a postoperative OSNA assay using SLNs stored at −80°C was performed in the remaining two studies. A previous SLN analysis in colon cancer patients performed by Vogelaar et al compared the performance of an OSNA with a routine pathological examination (single HE staining) and multilevel fine pathological examination (IHC with pan-cytokeratin antibody staining). They showed that the performance of the OSNA and fine pathological examination were superior to that of the routine pathological examination. Furthermore, an upstaging rate of 46.5% was obtained by combining the two methods together.

The average total time needed to complete the OSNA assay is approximately 40 minutes, and this length of time is acceptable for the intraoperative examination of SLNs. Two studies performed intraoperative OSNA assays to evaluate not only its diagnostic performance but also the time interval between surgery and postoperative adjuvant chemotherapy. Although both studies were small pilot studies, they showed that an intraoperative OSNA assay was able to significantly reduce the time between surgery and adjuvant chemotherapy in node-positive CRC patients. Recent population studies and meta-analysis confirmed that starting adjuvant chemotherapy beyond 8 weeks postoperatively was associated with a decreased overall survival compared to initiation within 8 weeks of surgery. Although the ideal start timing of adjuvant chemotherapy could never be tested in prospective randomized controlled trials for obvious ethical reasons, in routine practice it should probably be introduced as early as possible after validation by a multidisciplinary team and according to patient recovery. In this regard, an OSNA assay, which can establish the LN status as soon as possible and minimize the risk of delayed adjuvant chemotherapy, seems to be useful in the management of high-risk stage II and stage III CRC patients.

### Table 3: Studies analyzing CRC metastasis in SLNs with OSNA

| Author            | Patients number (Sample number) | Injected dye                              | Intraoperative OSNA assay | The number of examined SLNs |
|-------------------|---------------------------------|-------------------------------------------|---------------------------|-----------------------------|
| Vogelaar et al    | 128 (325)                       | Patent Blue Dye V or Indocyanine Green     | No                        | 3.0 (median)                |
| Marhic et al      | 17                              | Blue dye                                  | Yes                       | Not shown                   |
| Yeung et al       | 16 (78)                         | Indocyanine Green                         | No                        | 4.9 (mean)                  |
| Esposito et al    | 34 (51)                         | Indocyanine Green                         | Yes                       | 1.0 (median)                |

Abbreviation: SLN, sentinel lymph node.
Patients with stage II CRC (T3-4N0M0) form a heterogeneous group with very different prognoses, and some patients with stage II CRC may have a worse prognosis than patients with low-risk stage III CRC (T1-3N1). The adjuvant treatment of patients with high-risk stage II colon cancer (poorly differentiated histology, presence of lymphovascular invasion, presence of perineural invasion, report of <12 LNs, bowel obstruction, and localized perforation) is an area of controversy in medical oncology. Therefore, increasing attention is now being focused on identifying unfavorable prognostic biomarkers that can be used to select patients for adjuvant chemotherapy. For example, circulating tumor DNA (ctDNA) as a novel biomarker for the identification of high-risk stage II CRC is now clinically used in Western countries, and several prospective clinical studies are ongoing. The analysis of ctDNA offers a non-invasive method of repeatedly evaluating the genomic profile of CRC patients using blood samples. The postoperative detection rate of ctDNA ranges from 10% to 15% among patients with stage II CRC and is associated with a poor prognosis.

Although the prognostic value of an OSNA analysis in stage II CRC is still unclear compared with that of ctDNA, more recent studies have hypothesized that positive results on an OSNA assay in stage II CRC patients correlate with a poor disease prognosis. Brito et al examined 753 LNs from pathologically node-negative colon cancer patients (n = 59) by an OSNA assay and showed that 28.8% of the patients had OSNA-positive LNs. In addition, most of the OSNA-positive patients (88.2%) were found to have LNs with micrometastases by a CK19 copy number analysis in the OSNA assay. Although the prognosis of colon cancer patients with pathologically negative OSNA-positive LNs was not evaluated in this study, such patients may have benefited from postoperative systemic therapy, as with pathologically node-positive patients.

Another study by Itabashi et al evaluated the prognosis of CRC patients with pathologically negative (pStage II) OSNA-positive LNs. A total of 15.7% (11/70) of pStage II patients had OSNA-positive nodes, and the 3-year disease-free survival (DFS) of such patients was extremely poor. Taken together, these studies suggest that OSNA can detect occult metastasis, such as macrometastasis, micrometastasis, and ITCs, regardless of tissue allocation bias for pathologically node-negative CRC patients. In addition, the detection of occult metastasis by an OSNA assay might be associated with disease recurrence and poor survival, which is consistent with the findings of previous reports analyzing other types of molecular detection not only in a meta-analysis of retrospective studies but also in a prospective multicenter trial. The prognostic value of an OSNA in pStage II CRC patients should be confirmed in larger studies for its clinical application. In Japan, a large prospective multicenter observation study (UMIN0000037532) detecting cancer cells by OSNA in node-negative stage II CRC evaluating the 3-year recurrence-free survival as the primary endpoint is ongoing. The result will help optimize treatment strategies in OSNA-positive pStage II CRC patients.

In Western countries, preoperative chemoradiotherapy (CRT) with total mesorectal excision (TME) is the standard therapy for rectal cancer. However, in Japan, TME plus lateral pelvic LN dissection (LLND) is performed for advanced low rectal cancer. Although the advantages of LLND in terms of local control have been established, it can cause sexual disorders and urinary dysfunction due to surgery-related damage to the pelvic plexus and the lateral ligaments of the rectum containing the neurovascular bundles. Therefore, there is an urgent need to develop ways of identifying patients, before or during surgery, who potentially have LPLN metastasis. Based on the fact that the presence of perirectal LN metastasis is one of the most significant predictive factors for LPLN metastasis, Miyake et al attempted to perform an intraoperative OSNA assay to detect perirectal LN metastasis in order to predict LPLN metastasis in rectal cancer patients undergoing surgical resection accompanied by LLND. In their study, LPLN metastases were present in 16% of patients (4/25), and all of these patients were positive on an OSNA for perirectal LN metastasis. The OSNA assay had a sensitivity of 100%, specificity of 86%, PPV of 57%, and NPV of 100% for predicting LPLN metastasis, and the authors concluded that the OSNA of perirectal LNs might be useful for selecting candidates for omission of LLND in rectal cancer surgery.

The LN status remains the most significant prognostic factor and an important component of the decision-making process regarding the adjuvant treatment for CRC cancer patients. In that respect, OSNA can be useful as an accurate, reproducible and automated assay for standardizing the LN metastasis evaluation. In addition, the OSNA may have the potential to detect occult metastasis that cannot be detected by a histopathological examination. Furthermore, Diaz-Mercedes et al analyzed the budget impact of introducing an OSNA assay in early-stage CRC patients and suggested that OSNA might not only have an economic benefit but also a clinical benefit in CRC patients, since it enabled more accurate staging, thereby avoiding unnecessary treatment. However, one disadvantage of the OSNA assay is that harvesting LNs requires crude manual dissection of the fresh specimen by a trained pathologist or technician. This step is crucial for any analysis but is not uniform, so missing nodes is unavoidable. Another disadvantage of OSNA assay is that using the whole LN means there is no tissue left for a subsequent examination following complete homogenization, making it impossible to conduct multiple tests of the LN for different biomarkers in the future.
The OSNA assay is useful for determining the treatment strategy for CRC patients, as summarized above. In addition, there are several potential advantages worth evaluating in the future. For example, conducting an OSNA assay to detect LN metastasis in rectal cancer patients who have undergone preoperative CRT and surgery might be useful. The presence of residual LN metastasis despite the involutional effect of CRT has been shown to be a major risk factor of local recurrence, distant recurrence, and poor survival.41,42 However, LNs after neoadjuvant therapy frequently show severe histological changes, including stromal fibrosis and elastosis with small clusters of residual and viable metastatic tumor cells. OSNA measures CK-19 derived from viable tumor cells and may thus be able to assess these changes more accurately than a pathological examination. Indeed, there have been a few reports describing the utility of an OSNA assay in breast and rectal cancer patients with neoadjuvant chemotherapy.17,43,44 In addition, an OSNA assay for the detection of extended LN metastasis, such as LPLN metastasis or para-aortic LN (PALN) metastasis, from CRC might be useful. PALN or LPLN metastasis from CRC has been shown to be a significant prognostic factor.45,46 An accurate diagnostic tool, such as the OSNA, seems effective for determining the treatment strategy after the evaluation of extended LN metastasis, as an accurate rate diagnosis can be achieved rapidly (intraoperatively if necessary), regardless of the preoperative treatment.

The main advantage of an OSNA assay over a pathological examination is that it provides objective and semi-quantitative data on the tumor volume in the whole LN rapidly with little to no effort by pathologists and with low inter-observer variability. As described above, an OSNA assay can help improve the treatment outcome of CRC patients in several respects, such as in the detection of high-risk stage II disease, the SLN analysis and the prediction of LPLN metastasis. Multicenter prospective studies with a large cohort of CRC patients are warranted to confirm such advantages of an OSNA assay, and technical refinements of the OSNA system are essential before it can be applied as a new standard.

DISCLOSURES
Conflicts of interest: Authors declare no conflicts of interest or financial ties to disclosure.

Author Contribution: Yukiharu Hiyoshi study conception design, Drafting the article. Takashi Akiyoshi study conception design. Yusuke Fukunaga study conception design.

ORCID
Yukiharu Hiyoshi  https://orcid.org/0000-0002-9209-554X
Takashi Akiyoshi  https://orcid.org/0000-0002-2321-1412

REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Goldstein NS. Lymph node recoveries from 2427 pT3 colorectal resection specimens spanning 45 years: recommendations for a minimum number of recovered lymph nodes based on predictive probabilities. Am J Surg Pathol. 2002;26:179–89.
3. Sloothaak D, Sahami S, van der Zaag-Loonen HJ, van der Zaag ES, Tanis PJ, Bemelman WA, et al. The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2014;40:263–9.
4. Weitz J, Kienle P, Magener A, et al. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res. 1999;5:1830–6.
5. Rahbari NN, Bork U, Motschall E, Thorlund K, Büchler MW, Koch M, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:60–70.
6. Tamaki Y, One-step nucleic acid amplification (OSNA): where do we go with it? Int J Clin Oncol. 2017;22:3–10.
7. Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807–16.
8. Zhou M, Wang X, Jiang L, Chen X, Bao X, Chen X. The diagnostic value of one step nucleic acid amplification (OSNA) in differentiating lymph node metastasis of tumors: a systematic review and meta-analysis. Int J Surg. 2018;56:49–56.
9. Wild JB, Iqbal N, Francombe J, Papetts T, Sanders DS, Ramcharan S. Is it time for one-step nucleic acid amplification (OSNA) in colorectal cancer? A systematic review and meta-analysis. Tech Coloproctol. 2017;21:693–9.
10. Croner RS, Schellerer V, Demund H, Schildberg C, Papadopulos T, Naschberger E, et al. One step nucleic acid amplification (OSNA) - a new method for lymph node staging in colorectal carcinomas. J Transl Med. 2010;8:83.
11. Yamamoto H, Sekimoto M, Oya M, Yamamoto N, Konishi F, Sasaki J, et al. OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Ann Surg Oncol. 2011;18:1891–8.
12. Güller U, Zettl A, Worni M, Langer I, Cabalzar-Wondberg D, Viehl CT, et al. Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? Cancer. 2012;118:6039–45.
13. Yamamoto N, Daito M, Hiyama K, Ding J, Nakabayashi K, Otomo Y, et al. An optimal mRNA marker for OSNA (One-step nucleic acid amplification) based lymph node metastasis detection in colorectal cancer patients. Jpn J Clin Oncol. 2013;43:264–70.
14. Vogelar FJ, Reimers MS, van der Linden RLA, van der Linden JC, Smit VTHBM, Lips DJ, et al. The diagnostic value of one-step nucleic acid amplification (OSNA) for sentinel lymph nodes in colon cancer patients. Ann Surg Oncol. 2014;21:3924–30.
15. Yamamoto H, Tomita N, Inomata M, Furuhatata T, Miyake Y, Noura S, et al. OSNA-assisted molecular staging in colorectal cancer: a prospective multicenter trial in Japan. Ann Surg Oncol. 2016;23:391–6.
16. Rakislova N, Montironi C, Aldecoa I, Fernandez E, Bombi JA, Jimeno M, et al. Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma. J Transl Med. 2017;15:14.
17. Miyake Y, Mizushima T, Hata T, Takahashi H, Hanada H, Shoji H, et al. Inspection of perirectal lymph nodes by one-step nucleic acid amplification predicts lateral lymph node metastasis in advanced rectal cancer. Ann Surg Oncol. 2017;24:3850–6.
18. Marhic A, Tremblay JF, Kaci R, Andre T, Eveno C, Pocard M. Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval. Dig Liver Dis. 2017;49:924–8.
19. Colling R, Yeung T, Hompes R, Kraus R, Cahill R, Mortensen N, et al. OSNA testing for lymph node staging in colorectal cancer. J Clin Pathol. 2017;70:638–9.
20. Aldecoa I, Montironi C, Planell N, Pellise M, Fernandez-Esparrach G, Gines A, et al. Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden. Surg Endosc. 2017;31:723–33.

21. Yeung TM, Wang LM, Colling R, Kraus R, Cahill R, Hompes R, et al. Intraoperative identification and analysis of lymph nodes at laparoscopic colorectal cancer surgery using fluorescence imaging combined with rapid OSNA pathological assessment. Surg Endosc. 2018;32:1073–6.

22. Brito MJ, Honavar M, Cipriano MA, Lopes J, Coelho H, Silva ARD, et al. Molecular staging of patients with colon cancer. The C-Closer-II Study: a multicentre study in Portugal. Acta Med Port. 2018;31:661–9.

23. Esposito F, Noviello A, Moles N, Coppola Bottazzi E, Baiamonte M, Macaione I, et al. Sentinel lymph node analysis in colorectal cancer patients using one-step nucleic acid amplification in combination with fluorescence and indocyanine green. Ann Coloproctol. 2019;35:174–80.

24. Diaz-Mercedes S, Archilla I, Camps J, de Lacy A, Gorostiaga I, Rosenberg R, et al. Molecular detection of lymph node metastasis in breast cancer patients using one-step nucleic acid amplification in combination with fluorescence and indocyanine green. Ann Coloproctol. 2019;35:174–80.

25. Itabashi M, Yamamoto H, Tomita N, Inomata M, Murata K, Hayashi S, et al. Lymph node positivity in one-step nucleic acid amplification is a prognostic factor for postoperative cancer recurrence in patients with stage II colorectal cancer: a prospective, multicenter study. Ann Surg Oncol. 2020;27:1077–83.

26. Croner RS, Geppert C-I, Bader FG, Nitsche U, Späth C, Rosenberg R, et al. Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study. Br J Cancer. 2014;110:2544–50.

27. Joosten JJ, Strobbe LJ, Wauters CA, Pruszczynski M, Wobbes T, Ruers TJ. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg. 1999;86:482–6.

28. Cahill RA, Leroy J, Marescaux J. Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature. BMC Surg. 2008;8:17.

29. Lips DJ, Koebrugge B, Jan Liefers G, van de Linden JC, Smit VTHBM, Pruif HFM, et al. The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute@ Study. BMC Surg. 2011;11:11.

30. Snook KL, Layer GT, Jackson PA, de Vries CS, Shousha S, Sinnett HD, et al. Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg. 2011;98:527–35.

31. Blagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305:2335–42.

32. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN classification for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28:264–71.

33. O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou J-I, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–8.

34. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020. [Online ahead of print].

35. Yamamoto H, Murata K, Fukunaga M, Ohnishi T, Noura S, Miyake Y, et al. Micrometastasis volume in lymph nodes determines disease recurrence rate of stage II colorectal cancer: a prospective multicenter trial. Clin Cancer Res. 2016;22:3201–8.

36. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.

37. Yokoyama S, Takifuji K, Hotta T, Matsuda K, Watanabe T, Mitani Y, et al. Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved. Surg Today. 2014;44:1097–103.

38. Georgiou P, Tan E, Gouvas N, Antoniou A, Brown G, Nicholls RJ, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol. 2009;10:1053–62.

39. Fujita S, Yamamoto S, Akasu T, Moriya Y. Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. Int J Colorectal Dis. 2009;24:1085–90.

40. Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255:1129–34.

41. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62.

42. Ogura A, Akiyoshi T, Yamamoto N, Kawachi H, Ishikawa Y, Noma H, et al. Does the depth of mesorectal invasion have prognostic significance in patients with ypT3 lower rectal cancer treated with preoperative chemoradiotherapy? Int J Colorectal Dis. 2017;32:349–56.

43. Osako T, Tsuda H, Horii R, Iwase T, Yamauchi H, Yagata H, et al. Molecular detection of lymph node metastasis in breast cancer patients treated with preoperative systemic chemotherapy: a prospective multicentre trial using the one-step nucleic acid amplification assay. Br J Cancer. 2013;109:1693–8.

44. Takamoto K, Shimazu K, Naoi Y, Shimomura A, Shimoda M, Kagara N, et al. One-step nucleic acid amplification assay for detection of axillary lymph node metastases in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2016;23:78–86.

45. Sahara K, Watanabe J, Ishibe A, Suwa Y, Suwa H, Ota M, et al. Long-term outcome and prognostic factors for patients with para-aortic lymph node dissection in left-sided colorectal cancer. Int J Colorectal Dis. 2019;34:1121–9.

46. Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum. 2006;49:1663–72.